Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Unicycive Therapeutics CEO Shalabh Gupta, M.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15 at 11 a.m. ET.
Unicycive Therapeutics will highlight its kidney disease pipeline at the H.C. Wainwright Global Investment Conference, with a live and archived webcast available to investors.
Unicycive Therapeutics, Inc. (NASDAQ:UNCY)
LOS ALTOS, CA, UNITED STATES, September 1, 2026 /EINPresswire.com/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11 a.m. ET.Unicycive Therapeutics, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/unicycive
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate-binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment, UNI-494, is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit https://unicycive.com/
Investor Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Unicycive Therapeutics
media@unicycive.com
SOURCE: Unicycive Therapeutics, Inc.
Additional Contact:
David Shapiro
B2i Digital, Inc.
+1 212-579-4844
david@b2idigital.com
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X
Other
Unicycive Therapeutics CEO Shalabh Gupta, M.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 11 am ET
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
